This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.
May 14th 2020
analyst reports
May 7th 2020
press releases
May 1st 2020
press releases
April 30th 2020
press releases
April 29th 2020
analyst reports
April 29th 2020
press releases
Upcoming Events
Whats next.
passion.
It takes a great deal of passion on the fight against cancer. We put our heart and soul into winning it.
know-how.
Our goal is to gather the strongest forces, the brightest minds and the most dedicated employees.
research.
Accurate research is the strong foundation for developing potential in effective treatment.
What is LAG3?
Lymphocyte-activation gene 3, or LAG-3 (LAG3), is a cell surface molecule with biologic effects on T cell function.
LAG3 is being used for many cancer immunotherapy treatments including Eftilagimod Alpha from Immutep.
